Thu.Nov 07, 2024

article thumbnail

Bird flu infections in farmworkers are going undetected, study shows

STAT

For months, as human cases of H5N1 bird flu associated with an outbreak of the virus in U.S. dairy cattle have mounted, one question has loomed larger than others: how many human infections are getting missed? Farmworkers face some of the most intense exposure to the bird flu virus, but resistance from farmers and a lack of health insurance and paid sick leave in the industry have limited the amount of testing of workers and hampered public health officials’ ability to track where the vir

362
362
article thumbnail

An RNAi renaissance is creating a new generation of startups

PharmaVoice

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A letter from the executive editor: A seminal moment for science journalism

STAT

Dear Readers, If you’re reading this, you have likely received letters from me before, highlighting STAT’s coverage of health and medicine and appealing to you to consider becoming a subscriber. I’m here to do so again. This time, though, feels different: We are at a unique moment in our country’s history, when an understanding of the issues that STAT covers is more relevant than ever before — to both our personal lives and our professional lives.

339
339
article thumbnail

Sarepta scraps a Duchenne drug as gene therapy sales rise

BioPharma Dive

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.

113
113
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Opinion: Tattoo-less radiation treatment is the future of cancer care

STAT

Tattoos are often seen as powerful expressions of individuality. In the medical world, however, they can serve as unwanted reminders of a difficult past. For cancer patients who require radiation therapy, permanent tattoos have long been necessary to help doctors accurately target and deliver treatment. While seemingly insignificant, these permanent spots can remind many patients of their cancer journey every time they see themselves in the mirror.

310
310
article thumbnail

Webinar recap: Boosting recruitment and retention with SDOH data

pharmaphorum

Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.

111
111

More Trending

article thumbnail

Novo sheds kidney drug licensed for $1.3bn a year ago

pharmaphorum

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based therapies for reducing cardiovascular risk and kidney disease in people with diabetes and obesity.

Diabetes 105
article thumbnail

These 6 companies are using AI to streamline clinical trials for pharma

STAT

In the last year, drugmakers have talked up the prospect of medicines discovered or designed by artificial intelligence.

317
317
article thumbnail

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

PharmaVoice

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.

100
100
article thumbnail

Blueprint's mastocytosis drug Ayvakit cleared for NHS use

pharmaphorum

NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis

105
105
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Two-thirds of community pharmacists 'negatively impacted' by GP action

The Pharmacist

Exclusive Two-thirds of community pharmacists have been negatively impacted by GP collective action to some extent, a survey by The Pharmacist has suggested. But just 13% of practice and primary care network (PCN) pharmacists have felt a negative effect. This comes as our sister title Pulse reveals that 70% of GPs in England are engaging […] The post Two-thirds of community pharmacists 'negatively impacted' by GP action appeared first on The Pharmacist.

article thumbnail

FDA proposes removal of oral Phenylephrine from OTC nasal decongestant products

Express Pharma

On 7 November 2024, the U.S. Food and Drug Administration (FDA) announced a proposal to remove oral phenylephrine from over-the-counter (OTC) drugs marketed as nasal decongestants. The proposal follows an agency review that concluded oral phenylephrine is ineffective in providing temporary relief of nasal congestion. Until a final order is issued, however, companies may continue to sell OTC products containing oral phenylephrine for nasal decongestion.

Dosage 87
article thumbnail

The Impact of Generic Drugs on Healthcare Costs

Drug Patent Watch

The rising cost of prescription drugs has become a significant public health concern, with millions of Americans struggling to afford their medications. One crucial factor in mitigating this issue is the increased use of generic drugs. Generic drugs have been instrumental in reducing healthcare costs, and their impact cannot be overstated.

88
article thumbnail

DBV Technologies’ stock slides as financial woes worsens

Pharmaceutical Technology

The company reported that it does not have sufficient cash reserves to operate for the next 12 months, can only fund operations into Q1 2025.

98
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

New NICE guidance clarifies HRT as ‘first line treatment’ for menopause symptoms

The Pharmacist

NICE has emphasised the importance of HRT in new guidance and clarified that cognitive behavioural therapy (CBT) should be an ‘add on’ treatment for menopausal symptoms. In its updated guidance, NICE has encouraged healthcare professionals to have ‘informed conversations’ with patients about the risks and benefits of HRT, and included a new ‘discussion aid’ to use […] The post New NICE guidance clarifies HRT as ‘first line treatment’ for menopause symptoms appeared first on The Pharmacist.

88
article thumbnail

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

Pharmaceutical Technology

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

105
105
article thumbnail

Sarepta pulls plug on Duchenne exon-skipping drug

pharmaphorum

Sarepta has halted development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy therapy Exondys 51.

111
111
article thumbnail

Minister for Science champions partnerships with private clinical sector in UK

Pharmaceutical Technology

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

98
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

New study to assess mpox vaccine in pregnant women and infants

Pharma Times

Trial to evaluate safety and efficacy of MVA-BN vaccine

Vaccines 121
article thumbnail

Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist

Outsourcing Pharma

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

93
article thumbnail

Elsevier backs Pistoia Alliance for AI in drug discovery

Pharma Times

New initiatives to tackle AI-related challenges in life sciences

112
112
article thumbnail

Senhwa Biosciences starts trial of silmitasertib in children with difficult to treat cancers

Outsourcing Pharma

The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.

75
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Drug Channels

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers' preparation.

68
article thumbnail

To 513(g) or not to 513(g)? That is the question

FDA Law Blog: Biosimilars

By Véronique Li, Senior Medical Device Regulation Expert & Jeffrey N. Gibbs — In most instances, it is clear if a product will be considered a “device” under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Sometimes, though, the question of classification defies an easy answer. When a company is unsure if its product is a device, there are a number of resources that can provide the answer, such as the device regulations at 21 CFR parts 800 – 898; any of the databases that cover pr

article thumbnail

Scientists discover how specific E. coli bacteria drive colon cancer

World Pharma News

Scientists have uncovered how certain E. coli bacteria in the gut promote colon cancer by binding to intestinal cells and releasing a DNA-damaging toxin. The study, published in Nature, sheds light on a new approach to potentially reduce cancer risk. The study was performed by the teams of Prof. Lars Vereecke (VIB-UGent Center for Inflammation Research) and Prof.

70
article thumbnail

Avid Bioservices to go private in $1.1bn private equity deal

pharmaphorum

Nasdaq-listed CDMO Avid Bioservices has agreed a $1.

108
108
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar

Big Molecule Watch

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In 2022, Shanghai Henlius Biotech granted Organon exclusive commercialization rights for HLX14 in the U.S., EU, and Canada. The filing for HLX14 is supported by data from studies including analytical assessments and two clinical trials.

article thumbnail

Moderna earnings beat forecasts, but analysts question whether sales spike will last

BioPharma Dive

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

article thumbnail

Specialty Value-Based Care is Improving Health Outcomes While Reducing Heath Care Costs

PharmExec

Delivering value-based care is expected to become even more prevalent, driven by factors such as patient comfort with digital tools and advancements in contractual arrangements.

52
article thumbnail

The rewards of planning ahead: designing for full GMP production at pilot scale

PharmaTech

Can biopharma manufacturers avoid extra costs, potential problems and wasted production time by designing a fully compliant (cGMP) manufacturing process early on? This article explores where planning ahead, using compendial raw materials of the highest quality and purity, can yield substantial benefits to both productivity and patient safety.

52
article thumbnail

Healthcare Email Marketing Strategies: A Guide for Pharma Executives

Pharma Marketing Network

In today’s digital world, healthcare email marketing is more than just sending out newsletters. It’s a strategic tool that, when done right, can boost engagement, nurture relationships with healthcare professionals (HCPs), and increase brand awareness. But how can pharma companies truly maximize the potential of email marketing? Let’s dive in and explore some proven strategies.

HIPAA 52